NovaBridge Biosciences (NBP) Receivables - Other (2018 - 2023)

NovaBridge Biosciences (NBP) has reported Receivables - Other for 5 consecutive years, with $2.0 million the latest figure, recorded in Q4 2023.

• In Q4 2023, Receivables - Other rose 70.51% year-over-year to $2.0 million; the TTM figure through Dec 2023 stood at $2.0 million (up 70.51% YoY), while the FY2023 annual figure was $2.0 million, changed N/A from the prior year.
• Receivables - Other climbed to $2.0 million in Q4 2023 per NBP's latest filing, from $1.2 million in the prior quarter.
• Across five years, Receivables - Other topped out at $39.7 billion in Q4 2021 and bottomed at $1.2 million in Q4 2022.
• Historically, Receivables - Other has averaged $5.7 billion across 4 years, with a median of $7.8 million in 2020.
• Annual changes were most pronounced in 2021 — Receivables - Other surged 505779.97% — and 2022, when it sank 100.0%.
• NovaBridge Biosciences' Receivables - Other stood at $7.8 million in 2020, then surged by 505779.97% to $39.7 billion in 2021, then tumbled by 100.0% to $1.2 million in 2022, then surged by 70.51% to $2.0 million in 2023.
• Business Quant data shows NBP's Receivables - Other at $2.0 million in Q4 2023, $1.2 million in Q4 2022, and $43.5 million in Q2 2022.